In a 65-year-old man presenting with suprapubic pain, what is the appropriate assessment and work‑up?

Assessment and Work-Up of Suprapubic Pain in a 65-Year-Old Male

In a 65-year-old man with suprapubic pain, begin with a focused history targeting pain characteristics and voiding symptoms, perform a digital rectal examination to assess the prostate, obtain urinalysis with culture, and complete a 3-day frequency-volume chart to differentiate between bladder-related conditions, benign prostatic obstruction, and chronic prostatitis/chronic pelvic pain syndrome. 1, 2

Initial History and Symptom Characterization

Pain Assessment

• Document the exact location of pain (suprapubic, perineal, penile tip, testicular), duration (symptoms ≥6 weeks suggest interstitial cystitis/bladder pain syndrome; ≥3 months suggest chronic prostatitis), and quality (many patients describe "pressure" or "discomfort" rather than frank pain). 1, 3
• Identify aggravating and relieving factors: pain that worsens with bladder filling and improves after urination points toward IC/BPS, whereas pain exacerbated by urination or ejaculation suggests chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). 1, 4, 3
• Ask specifically about dietary triggers (caffeine, alcohol, acidic foods, spicy foods) and whether abdominal pressure worsens symptoms. 1, 4

Voiding Symptom Evaluation

• Assess both storage symptoms (daytime frequency >8 voids/24 hours, nocturia ≥2 voids/night, urgency) and voiding symptoms (weak stream, hesitancy, intermittency, straining, incomplete emptying). 1, 2
• Determine the degree of bother using the International Prostate Symptom Score (IPSS): 0-7 is mild, 8-19 is moderate, 20-35 is severe. 1, 2
• Distinguish urgency quality: IC/BPS patients void to avoid or relieve pain, whereas overactive bladder patients void to prevent incontinence. 3

Additional History Elements

• Review current medications for agents that worsen urinary symptoms (anticholinergics, antihistamines, decongestants, diuretics). 1, 2
• Screen for sexual dysfunction: pain with intercourse or ejaculation strongly suggests CP/CPPS or IC/BPS. 1, 4
• Assess for neurological symptoms (lower extremity weakness, saddle anesthesia, bowel dysfunction) that would mandate immediate urologic referral. 1, 2

Physical Examination

Focused Examination Components

• Suprapubic palpation to detect bladder distention indicating possible urinary retention. 1, 2
• Digital rectal examination (DRE) to assess prostate size, consistency, symmetry, and tenderness; nodules or induration require immediate urologic referral for possible prostate cancer. 1, 2, 4
• External genitalia inspection and assessment of perineal sensation to identify neurogenic causes. 2
• Evaluate for lower extremity edema which can contribute to nocturnal polyuria through fluid redistribution. 2

Essential Laboratory Testing

Mandatory Initial Tests

• Urinalysis with dipstick and microscopy to detect infection, hematuria, proteinuria, or glucosuria; any hematuria (microscopic or gross) mandates immediate urologic referral. 1, 2, 3
• Urine culture if urinalysis is abnormal to guide antibiotic therapy; however, do not initiate empiric antibiotics when urinalysis is normal, as this provides no benefit and promotes resistance. 2, 3
• Serum PSA measurement should be offered when life expectancy is ≥10 years and the result could influence management (e.g., prompting prostate cancer evaluation); an abnormal PSA requires immediate urologic referral. 1, 2

Voiding Diary

• Obtain a 3-day frequency-volume chart recording the time and volume of each void, total fluid intake, and any pain episodes to distinguish overactive bladder (small frequent voids) from nocturnal polyuria (large nighttime voids >33% of 24-hour output) and from polydipsia (total output >3 L/day). 1, 2

Differential Diagnosis Framework

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

• Consider IC/BPS when pain is perceived as bladder-related, lasting ≥6 weeks, typically suprapubic but may extend throughout the pelvis, worsening with bladder filling and improving after voiding. 1, 3
• Urinary frequency (92% of patients) and urgency (84%) are nearly universal but patients void to relieve pain rather than prevent incontinence. 3
• Cystoscopy should be performed if Hunner lesions are suspected, as this is the only reliable way to diagnose them and these patients respond well to targeted treatment. 1, 3

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

• CP/CPPS presents with pain in the perineum, suprapubic region, testicles, or penile tip, often exacerbated by urination or ejaculation, persisting ≥3 months. 1, 4, 3
• The clinical characteristics overlap substantially with IC/BPS; some men meet criteria for both conditions and treatment can include therapies for both. 1, 3
• DRE may reveal pelvic floor muscle spasm or prostatic tenderness, though findings are often nonspecific. 4

Benign Prostatic Obstruction (BPO)

• BPO typically presents with voiding symptoms (weak stream, hesitancy, straining) more prominently than pain, though suprapubic discomfort from bladder distention can occur. 1
• DRE reveals benign prostatic enlargement (smooth, symmetric, rubbery consistency). 1, 2
• Post-void residual (PVR) measurement by bladder ultrasound is indicated when obstructive symptoms are prominent; PVR >100-200 mL is clinically significant and warrants urologic referral. 2

Selective Additional Testing

When to Perform Additional Studies

• Uroflowmetry (if available) provides objective assessment; peak flow (Qmax) <10 mL/second indicates severe obstruction requiring immediate urologic referral. 1, 2
• Cystoscopy is reserved for suspected Hunner lesions in IC/BPS or when urethral stricture is suspected (history of catheterization, trauma, sexually transmitted infections, split urinary stream). 1, 2, 3
• Urodynamic studies are not recommended for routine diagnosis of IC/BPS but may be indicated before surgery or when diagnosis remains uncertain after initial evaluation. 1, 2

Immediate Urologic Referral Criteria (Before Initiating Treatment)

Refer immediately to urology if any of the following are present:

• Hematuria (microscopic or gross) not attributable to infection. 1, 2
• Abnormal PSA exceeding locally accepted reference ranges. 1, 2
• Suspicious DRE findings (nodules, asymmetry, induration). 1, 2
• Recurrent urinary tract infections (≥2 episodes in 6 months or ≥3 in 12 months). 1, 2
• Palpable bladder or PVR >200-300 mL suggesting urinary retention. 1, 2
• Neurological disease affecting bladder function (multiple sclerosis, Parkinson's disease, spinal cord injury). 1, 2
• Severe obstruction with Qmax <10 mL/second on uroflowmetry. 1, 2

Initial Management for Non-Urgent Cases

Behavioral Modifications (First-Line for All Patients)

• Target approximately 1 liter of urine output per 24 hours by adjusting fluid intake; excessive hydration worsens symptoms in older men. 1, 2
• Reduce evening fluid intake to minimize nocturia. 1, 2
• Avoid bladder irritants including caffeine, alcohol, carbonated beverages, artificial sweeteners, and heavily seasoned foods. 1, 2

Pharmacologic Therapy Based on Predominant Symptoms

• For moderate-to-severe voiding symptoms (IPSS 8-35) without red flags, initiate alpha-blocker monotherapy (e.g., tamsulosin 0.4 mg daily) and assess response at 2-4 weeks. 1, 2
• For pain-predominant symptoms suggesting IC/BPS or CP/CPPS, initiate multimodal pain management including pharmacological approaches and stress management; consider referral to pain specialist if inadequate response. 1

Common Pitfalls to Avoid

• Do not dismiss patients who describe "pressure" rather than "pain"; this terminology is common in IC/BPS, CP/CPPS, and other pelvic pain syndromes. 1, 3
• Do not initiate empiric antibiotics when urinalysis is normal; this promotes antimicrobial resistance and disrupts protective flora without providing benefit. 2, 3
• Do not assume all suprapubic pain in older men is due to BPH; IC/BPS and CP/CPPS are underdiagnosed in men and require different treatment approaches. 1, 3
• Do not start anticholinergic therapy without first measuring PVR; these agents can precipitate acute urinary retention in patients with elevated residual volumes. 2

Follow-Up Strategy

• Schedule initial follow-up at 4-12 weeks after treatment initiation to assess efficacy and adverse effects using repeat IPSS and symptom assessment. 1, 2
• Annual follow-up is recommended for patients with successful treatment to detect symptom progression or complications. 2